DKP Microparticles with Defined Surface Area for Deep-Lung Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery systems face challenges in efficiently delivering drugs to the lungs due to instability in the gastrointestinal tract and difficulties in navigating natural barriers, leading to inefficient absorption and uniform delivery.
Innovation Solution
The development of diketopiperazine (DKP) microparticles with a specific surface area ranging from 35 to 67 m²/g, which enhance aerodynamic performance and drug adsorption, allowing for improved pulmonary delivery of drugs such as insulin and other peptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If drugs are administered orally, then ease of administration and patient compliance are improved, but drug stability in the gastrointestinal tract deteriorates leading to low or variable potency
Solution Approach 1:
The invention segments the drug delivery process by using DKP microparticles as intermediate carriers. The microparticles are formed by self-assembly of DKP molecules, creating discrete particulate structures that encapsulate or adsorb the active drug substance. This segmentation protects the drug from gastrointestinal degradation while maintaining oral administration convenience.
Solution Approach 2:
The DKP microparticles serve as an intermediary between the drug substance and the gastrointestinal environment. The microparticle matrix acts as a protective barrier that shields unstable drugs from acidic and enzymatic conditions in the GI tract, while still allowing the drug to be released at the target site in the lungs.
2Reliability
If drugs are delivered to the lungs, then drug stability and absorption efficiency are improved, but difficulty in navigating natural barriers and achieving uniform delivery worsens
Solution Approach 1:
The invention optimizes critical parameters of the DKP microparticles including specific surface area (35-67 m²/g), particle size distribution, and aerodynamic properties. By controlling these parameters, the microparticles achieve optimal respirability and can navigate the complex barriers of the respiratory tract efficiently, depositing uniformly in the lung tissue.
Solution Approach 2:
The DKP microparticles exhibit spherical or near-spherical morphology which is optimal for pulmonary delivery. The curved surface geometry reduces turbulence during inhalation, improves airflow dynamics in the respiratory tract, and facilitates uniform deposition in the lung parenchyma compared to irregularly shaped particles.
3Quantity of substance
If DKP microparticles have high specific surface area, then drug adsorption capacity is improved, but aerodynamic performance deteriorates
Solution Approach 1:
The invention identifies and optimizes the specific surface area parameter within a narrow range (35-67 m²/g) that balances two competing requirements: sufficient surface area for drug adsorption while maintaining low enough particle density and size for optimal aerodynamic performance and deep lung penetration. This precise parameter control resolves the contradiction between adsorption capacity and respirability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The DKP microparticles exhibit improved aerodynamic performance and drug adsorption, enabling effective delivery to the deep lung with a respirable fraction exceeding 50% and efficient inhalation systems that ensure uniform dosage.
Implementation Method 1
drug adsorption
Data Source
AI summary
Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.